Fate Therapeutics, Inc. (FATE): Price and Financial Metrics

Fate Therapeutics, Inc. (FATE): $6.96

0.08 (+1.16%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

C

Add FATE to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#110 of 357

in industry

FATE Price/Volume Stats

Current price $6.96 52-week high $7.74
Prev. close $6.88 52-week low $1.63
Day low $6.75 Volume 1,536,900
Day high $7.11 Avg. volume 3,047,965
50-day MA $4.87 Dividend yield N/A
200-day MA $3.76 Market Cap 686.27M

FATE Stock Price Chart Interactive Chart >

FATE POWR Grades

  • FATE scores best on the Value dimension, with a Value rank ahead of 79.57% of US stocks.
  • The strongest trend for FATE is in Growth, which has been heading down over the past 26 weeks.
  • FATE's current lowest rank is in the Stability metric (where it is better than 2.23% of US stocks).

FATE Stock Summary

  • Of note is the ratio of FATE THERAPEUTICS INC's sales and general administrative expense to its total operating expenses; only 11.59% of US stocks have a lower such ratio.
  • As for revenue growth, note that FATE's revenue has grown 53.9% over the past 12 months; that beats the revenue growth of 91.43% of US companies in our set.
  • The volatility of FATE THERAPEUTICS INC's share price is greater than that of 90.76% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to FATE THERAPEUTICS INC, a group of peers worth examining would be CCCC, AEVA, CUE, BCYC, and BOLT.
  • Visit FATE's SEC page to see the company's official filings. To visit the company's web site, go to www.fatetherapeutics.com.

FATE Valuation Summary

  • In comparison to the median Healthcare stock, FATE's price/sales ratio is 16.67% lower, now standing at 3.5.
  • Over the past 125 months, FATE's price/sales ratio has gone down 61.7.

Below are key valuation metrics over time for FATE.

Stock Date P/S P/B P/E EV/EBIT
FATE 2023-12-29 3.5 0.9 -2.1 -2.5
FATE 2023-12-28 3.7 1.0 -2.2 -2.6
FATE 2023-12-27 3.4 0.9 -2.1 -2.4
FATE 2023-12-26 3.5 0.9 -2.1 -2.4
FATE 2023-12-22 3.2 0.8 -1.9 -2.3
FATE 2023-12-21 3.1 0.8 -1.9 -2.2

FATE Growth Metrics

    The 2 year price growth rate now stands at 1.56%.
  • Its 5 year cash and equivalents growth rate is now at 142.06%.
  • Its 5 year net cashflow from operations growth rate is now at -207.58%.
Over the past 49 months, FATE's revenue has gone up $64,907,000.

The table below shows FATE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 69.013 -243.112 -293.979
2022-06-30 68.257 -221.44 -253.724
2022-03-31 63.12 -200.387 -232.752
2021-12-31 55.846 -162.87 -212.151
2021-09-30 54.675 -113.241 -196.641
2021-06-30 48.008 -110.599 -212.017

FATE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FATE has a Quality Grade of D, ranking ahead of 19.68% of graded US stocks.
  • FATE's asset turnover comes in at 0.058 -- ranking 313th of 680 Pharmaceutical Products stocks.
  • RMTI, SYBX, and PTE are the stocks whose asset turnover ratios are most correlated with FATE.

The table below shows FATE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.058 1 -0.324
2021-03-31 0.054 1 -0.384
2020-12-31 0.057 1 -0.550
2020-09-30 0.039 1 -0.586
2020-06-30 0.033 1 -0.572
2020-03-31 0.036 1 -0.625

FATE Price Target

For more insight on analysts targets of FATE, see our FATE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $109.83 Average Broker Recommendation 1.47 (Moderate Buy)

Fate Therapeutics, Inc. (FATE) Company Bio


Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops programmed cellular immunotherapies for cancer and immune disorders in the United States. The company was founded in 2007 and is based in San Diego, California.


FATE Latest News Stream


Event/Time News Detail
Loading, please wait...

FATE Latest Social Stream


Loading social stream, please wait...

View Full FATE Social Stream

Latest FATE News From Around the Web

Below are the latest news stories about FATE THERAPEUTICS INC that investors may wish to consider to help them evaluate FATE as an investment opportunity.

Fate Therapeutics (FATE) Upgraded to Buy: Here's Why

Fate Therapeutics (FATE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | December 22, 2023

12 Most Promising Cancer Stocks According to Analysts

In this piece, we will take a look at the 12 most promising cancer stocks according to analysts. If you want to skip our overview of the latest trends in the cancer treatment sector, then you can take a look at the 5 Most Promising Cancer Stocks According to Analysts. The advent of technology and […]

Yahoo | December 18, 2023

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company granted a non-qualified stock option to one newly-hired employee to purchase a total of 350,000 shares of the Company’s common stock at an exercise price per share of $

Yahoo | December 13, 2023

Fate Therapeutics (FATE) Up 10.3% Since Last Earnings Report: Can It Continue?

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 8, 2023

Fate Therapeutics, Inc. (NASDAQ:FATE) Q3 2023 Earnings Call Transcript

Fate Therapeutics, Inc. (NASDAQ:FATE) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Welcome to the Fate Therapeutics Third Quarter 2023 Financial Results Conference Call. At this time, all participants are mode. The call is being webcast live on the Investors section of Fate’s website at fatetherapeutics.com. As a reminder, today’s call is being recorded. […]

Yahoo | November 9, 2023

Read More 'FATE' Stories Here

FATE Price Returns

1-mo 52.63%
3-mo 205.26%
6-mo 156.83%
1-year 20.21%
3-year -91.93%
5-year -56.34%
YTD 86.10%
2023 -62.93%
2022 -82.76%
2021 -35.65%
2020 364.64%
2019 52.53%

Continue Researching FATE

Here are a few links from around the web to help you further your research on Fate Therapeutics Inc's stock as an investment opportunity:

Fate Therapeutics Inc (FATE) Stock Price | Nasdaq
Fate Therapeutics Inc (FATE) Stock Quote, History and News - Yahoo Finance
Fate Therapeutics Inc (FATE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!